Why the study?
GDF-15 is an established cardiovascular risk marker implicated in tumour biology, but its relation to other cardiac biomarkers and prognostic value in treatment-naive cancer patients required exploration.
Does elevated plasma GDF-15 predict all-cause mortality in treatment-naïve cancer patients?
Population
555 consecutive treatment-naive cancer patients prior to anticancer therapy
Comparison
GDF-15 levels across tumor entities and clinical characteristics
Design
Prospective cohort study
Authors
Loading...
May flag subclinical cardiac-inflammatory burden at cancer diagnosis but should not change practice; leaves open incremental utility and hematologic exceptions.
Does elevated plasma GDF-15 predict all-cause mortality in treatment-naïve cancer patients?
Elevated plasma GDF-15 is associated with disease severity, systemic inflammation, subclinical organ impairment, and poor prognosis in treatment-naïve patients with solid tumors, highlighting its potential role in cardio-oncology.
Arfsten et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: